BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells

Stem Cells for ALS: Everything You Need to Know

By Leave a Comment

Although records of ALS aren’t kept everywhere in the country, doctors estimate that between 12,000 and 15,000 people in the United States have it. Though this nerve disease is relatively rare, the illness has a devastating, paralyzing effect on the people who have it.

As of now, ALS isn’t curable. However, many clinical trials show promising results in treating it in the future. Among these trials, the use of stem cells for ALS stands out as an innovative solution.

In this article, we’ll cover everything you need to know about where stem cell therapy stands as a possible solution to Lou Gehrig’s disease. Let’s get started! [Read more…]

Proteintech and HebeCell to Collaborate on Nanobody iPSC-derived NK Cells

By Leave a Comment

CHICAGO & NATICK, Massachusetts, Nov 11, 2020–Proteintech and HebeCell  announce their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor (nCAR) technology for the development and commercialization of iPSC-derived natural killer (iPSC-nCAR-NK) cells, a promising cellular immunotherapy treatment for cancer and other diseases.

Proteintech’s recent acquisition of nanobody manufacturer, ChromoTek, has made them a leading player in the nanobody space. ChromoTek’s high-performing camelid single-chain recombinant reagents, also known as nanobodies, fuel breakthrough research discoveries.

HebeCell holds unique expertise and intellectual property in induced pluripotent stem cells (iPSC) and their lineage specific differentiation, especially toward natural killer (NK) cells. Although NK cells are best known for killing virally infected cells, they also play key roles in detecting and controlling early signs of cancer.

“Partnering with Proteintech will give both companies a competitive edge,” said Dr. Allen Feng, the Founder and Chief Scientific Officer of HebeCell, “Our combined expertise and technologies create a unique and special collaboration that will improve the treatment and care of cancer patients.”

Dr. Jason Li, CEO of Proteintech added, “I’ve known Dr. John Lu, Founder and CEO of HebeCell, for many years and I’m glad we have an opportunity to work together on this important project. With HebeCell’s proprietary NK cells and Proteintech’s nanobodies, the two companies can transform the future of cancer therapy. [Read more…]

FUJIFILM Cellular Dynamics and Lonza agree to expand the availability and use of induced pluripotent stem cell technology

By Leave a Comment

– FUJIFILM Cellular Dynamics grants Lonza a non-exclusive right to use their patents related to iPSC generation, including episomal vectors and reprogramming factors, for development and clinical manufacture of iPSC lines for cell therapies
– Lonza grants FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector™ technology
– The agreement enables drug developers to leverage both companies expertise and technologies for the generation of human-induced pluripotent stem cells through licensing agreements

[Read more…]

Developing Induced Pluripotent Stem Cells (iPSCs) as Cell Therapeutics

By Leave a Comment

Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types for use in human patients. Within a preclinical context, cell types differentiated from iPSCs are tested for their therapeutic response by using animal models. Then, clinical trials are conducted to assure that essential parameters, such as tumorigenicity, dose toxicity, and immunogenicity, are assessed before authorizing the product for use in human patients. [Read more…]

Induced Pluripotent Stem Cell Clinical Trials, by Disease and Country

By

A number of induced pluripotent stem cell (iPSC) derived disease models have resulted in the discovery of new drugs that have been tested in iPSC-derived cells for efficacy and potential toxicities. Genome editing technologies have also added a new dimension to to the development of personalized medicine using iPSCs. In some cases, iPSC-derived cell types are being explored as novel cell therapeutics. [Read more…]

BioInformant's World-Class Clients